This is the third consecutive year of $1 million or more in grants distributed to New Investigators.
NORTHFIELD, Ill., July 17, 2018 -- The Leukemia Research Foundation (LRF) today announced $1.167 million in new blood cancer research funding for the 2018-2019 fiscal year. The LRF provides one-year grants of up to $100,000 to New Investigators, scientists who are establishing their own laboratories and are no longer under the tutelage of a senior scientist mentor, to facilitate pursuit of groundbreaking research ideas that could lead to significant breakthroughs.
Congratulations to the following list of grantees.
Daniel Herranz Benito, Ph.D. - Rutgers Cancer Institute of New Jersey
Dissecting the role of PKM2 in NOTCH1-induced T-ALL
Kishore Challagundla, Ph.D. - University of Nebraska Medical Center
Exosomic miRNAs and PD-L1 in AML Therapy Resistance
Shunji Egusa, Ph.D. - The University of North Carolina Charlotte
Au nano-linker: Turning standard AML drugs into lineage-targeted therapeutics
Jin Seon Im, M.D., Ph.D. - The University of Texas MD Anderson Cancer Center
Third Party Gene-Modified iNK t cells to Prevent GVHD and Relapse after Transplantion
Matthew Mei, M.D. - City of Hope National Medical Center
The Impact of Somatic /mutations on Allogeneic Transplantation Outcomes in Chronic Myelomonocytic Leukemia
Esther A. Obeng, M.D., Ph.D. – St. Jude Children's Research Hospital
Uncovering how SF3B1 and TET2 mutations cooperate to develop aggressive MDS
Chintan Parekh, M.D. - Children's Hospital Los Angeles
Molecular characterization of minimal residual disease cells in pediatric ALL
Paulina Podszywalow-Bartnicka, Ph.D. - Nencki Institution of Experimental Biology (Warsaw, Poland)
Synthetic lethality in leukemia - effect of PARP1 inhibitors in bone marrow niche
Brittany Knick Ragon, M.D. - Levine Cancer Insititute
Identification of molecular and genetic determinants of response to hypomethylation agents in AML
Russel J. H. Ryan, M.D. - University of Michigan
Identifying Unique /myc Enhancer Dependencies in B-Lymphoblastic Leukemia
Cristina Scielzo, Ph.D. – IRCCS (Milan, Italy)
Decipher the dynamic expression of targetable signalling pathways in CLL tissues by exploiting new 3D models
Yue Wei, Ph.D. - The University of Texas MD Anderson Cancer Center
Characterize the pathological role and therapeutic potential of histone demethylase KDM6B in MDS
“Providing grants to New Investigators is critically important because federal funding for blood cancer research has dropped by 25 percent in the last several years,” said LRF Executive Director Kevin Radelet. “We’re in the midst of losing an entire generation of cancer researchers because New Investigators with fresh, groundbreaking ideas can’t get the funding they need to develop the data required for greater funding from the National Institutes of Health (NIH). Grants from the Leukemia Research Foundation not only advance blood cancer science but also jumpstarts careers for these scientists.”
Every year, dozens of research projects are submitted to the LRF for funding. The projects are reviewed by the LRF’s Medical Advisory Board (MAB), chaired by Dr. Patrick Stiff, Director of the Cardinal Bernardin Cancer Center at Loyola University Medical Center in Maywood, Ill. The MAB evaluates and ranks the projects using the same scoring method as used by the National Institutes of Health, then submits its recommendations for funding to the LRF.
For more information about the LRF and its Hollis Brownstein Research Grants Program, visit www.allbloodcancers.org.
About The Leukemia Research Foundation (LRF)
The Leukemia Research Foundation, headquartered in Northfield, Ill., is committed to funding research and providing support to people affected by blood cancers. The Leukemia Research Foundation is dedicated to conquering all blood cancers by funding research into their causes and cures, and enriching the quality of life of those touched by these diseases. For 72 years, thousands of volunteers and 22 chapters have helped the Foundation raise more than $75 million to help fund research specifically targeting aspiring, eager, and innovative scientists and physicians around the world.
Leukemia Research Foundation information is available at www.allbloodcancers.org, or by calling (847) 424-0600.
# # #
For additional information call:
Carl Alston, Director of Communications
(847) 919-6250 office
(630) 202-8294 mobile